Vanguard will pay final distributions (dividends) for its ASX exchange-traded funds (ETFs) today.

Here is a summary of the final distributions that investors will receive on Thursday.

The Vanguard Australian Shares Index ETF (ASX: VAS) will pay a dividend of 48.83 cents per unit.

Vanguard Australian Shares High Yield ETF (ASX: VHY) will pay 40.65 cents per unit.

The Vanguard MSCI Australian Small Companies Index ETF (ASX: VSO) will pay 219.69 cents per unit.

Vanguard Australian Fixed Interest Index ETF (ASX: VAF) will pay a dividend of 53.37 cents per unit.

The Vanguard Australian Property Securities Index ETF (ASX: VAP) will pay 147.02 cents per unit.

Vanguard Ethically Conscious Australian Shares ETF (ASX: VETH) will pay 34.38 cents per unit.

Vanguard MSCI Australian Large Companies Index ETF (ASX: VLC) will pay a dividend of 26.66 cents per unit.

What about ETFs holding international shares?

Vanguard MSCI Index International Shares ETF (ASX: VGS) will pay 81.54 cents per unit in dividends.

The currency-hedged version of VGS, Vanguard MSCI Index International Shares (Hedged) ETF (ASX: VGAD), will pay 293.51 cents per unit.

The Vanguard MSCI International Small Companies Index ETF (ASX: VISM) will pay 322.63 cents per unit.

Vanguard S&P 500 US Shares Index ETF (ASX: V500) will pay 11.45 cents per unit.

Vanguard FTSE Europe Shares ETF (ASX: VEQ) will pay 97.49 cents per unit.

The Vanguard Diversified High Growth Index ETF (ASX: VDHG) will pay 121.56 cents per unit.

Vanguard Ethically Conscious International Shares Index ETF (ASX: VESG) will pay 64.40 cents per unit.

Mega dividends

The two biggest payers on Vanguard’s mid-year schedule of dividends are as follows.

Vanguard Global Minimum Volatility Active ETF (ASX: VMIN) is an actively managed ETF invested in about 200 international shares.

The ETF aims to deliver lower volatility than the FTSE Global All Cap Index (AUD Hedged), before fees.

VMIN ETF will pay a monster dividend of 377.42 cents per unit.

This is a quarterly distribution.

When Vanguard announced its estimated distributions on 26 June, VMIN closed at $64.32 per unit.

So, this mega dividend amounts to an impressive 5.9% dividend yield for the quarter.

VMIN’s unit price has since dropped by the dividend amount, as usual, after going ex-dividend on 1 July.

Vanguard Global Value Equity Active ETF (ASX: VVLU) is also actively managed.

VVLU targets global value stocks drawn mainly from the FTSE Developed All Cap Index and the Russell 3000 Index.

VVLU ETF will pay the largest dollar-amount dividend on Vanguard’s schedule at 619.93 cents per unit.

This is also a quarterly distribution.

On 26 June, VVLU ETF closed at $83.19 per unit.

That means today’s distribution provides an even more impressive dividend yield of 7.5%.

The post Own Vanguard ASX ETFs? It’s dividend payday! appeared first on The Motley Fool Australia.

More reading

• 3 ways to get from $100,000 to $500,000 in retirement savings
• 3 amazing ASX ETFs I’d buy this month
• How to invest $20,000 in ASX ETFs in July
• Analysts are still bullish on SpaceX shares after Nasdaq inclusion. Here is what that means for ASX investors
• The best Vanguard ETFs to buy and hold

Motley Fool contributor Bronwyn Allen has positions in Vanguard Msci Index International Shares ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Australian Shares High Yield ETF and Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX healthcare stock EMvision Medical Devices Ltd (ASX: EMV) could be a growth stock about to take off according to a new report from Bell Potter. 

It soared 15% higher yesterday after the company released its quarterly report. 

The company is developing portable brain imaging devices to enable faster stroke diagnosis. 

It is commercialising technology developed from a decade of University of Queensland research. Its flagship emu device is designed for hospital use. Additionally, the First Responder device is a helmet-sized scanner for ambulances, aiming to improve stroke diagnosis before patients reach hospital.

What did the company announce?

Yesterday, EMvision released its quarterly activities report which included: 

• Strong balance sheet position maintained, with cash reserves of $17.1m as at 30 June 2026 and $4.6m in non-dilutive funding remaining under current grant programs.
• Pivotal (Validation) Trial, has surpassed key enrolment milestones, building momentum toward FDA De Novo clearance for EMVision’s emu point-of-care brain scanner. 
• Successful First Responder aeromedical feasibility and usability study with Royal Flying Doctor Service (RFDS) completed, with flight nurses and patients rating the prototype device favourably in real-world operation.

Following the results, the team at Bell Potter provided updated guidance on the ASX healthcare stock. 

Forthcoming engagement with FDA on emu trial

In its market update, EMV advised it is preparing for a pre-submission (Q-Sub) meeting with the FDA. This will cover the proposed claims and performance thresholds required for its De Novo clearance. 

Bell Potter said the outcome of the meeting could be meaningful and set a tone for investor sentiment. 

The primary objective of the pivotal trial is to demonstrate haemorrhage detection sensitivity & specificity at >80%. The inclusion of the ischaemic stroke cohort requires a minor adjustment to the required sample to ensure the sub-cohort meets statistical objectives. Including both types of strokes, is expected to reduce intervention delays and improve patient outcomes, expanding clinical utility from product launch. 

The broker said this inclusion is expected to push out timelines on the result to well into CY27. 

However, the recent publication of the emu study provides independent peer-reviewed validation of the AI foundations underpinning the emu Brain Scanner / First Responder.  Publication should serve to build audience awareness and credibility.

Big upside for ASX healthcare stock 

Following the update, Bell Potter retained its speculative buy recommendation on this ASX healthcare stock. 

It also retained its 12 month price target of $3.15.

From yesterday’s closing price, this indicates a near 80% rise. 

The first of three feasibility studies has concluded successfully, with the aeromedical study with the RFDS showing the First Responder is intuitive, practical and suited to the specific environment.

The Mobile Stroke Unit study is near completion and should be reported on in 1Q27, while the road ambulance study is in the planning stage. These studies are expected to lead to a 510(k) submission over the medium term.

The post This healthcare stock just jumped 15% and experts are tipping a further 80% rise  appeared first on The Motley Fool Australia.

More reading

• Why Nick Scali shares are set for a 36% rebound: Expert
• Top broker tips 47% upside for this ASX financials stock 
• 2 ASX small-caps with 40% upside
• Is this ASX consumer discretionary stock a buy after jumping 10% yesterday?
• Top broker tips 37% upside for this exciting ASX healthcare stock

Motley Fool contributor Aaron Bell has positions in EMVision Medical Devices. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended EMVision Medical Devices. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Echo IQ Ltd (ASX: EIQ) has been one of the fastest-growing stocks on the ASX this year.

Since January, it has risen over 500%. Fortunately for prospective investors, the team at Morgans believes this growth is set to continue. 

Company overview 

EchoIQ develops artificial intelligence for the cardiac diagnostics sector and supplies software to the health fund and insurance sectors. 

It operates through the Houston WeHave Software and Echo IQ segments. 

The Houston WeHave Software segment offers products and services across defence and other sectors. 

The Echo IQ segment focuses on developing artificial intelligence software that aids in predicting Aortic Stenosis heart condition.

In 2026, it has risen more than 500% as investors responded to a series of major commercial milestones. 

This includes its strategic partnership with Pro Medicus, new US market opportunities, a $110 million capital raising, and expanded access to a large cardiovascular imaging dataset to strengthen its AI-powered diagnostic platform. 

The rally has also been fuelled by optimism that these developments could accelerate US commercialisation and establish Echo IQ as a leading player in AI-driven cardiovascular diagnostics. 

Morgans upgrades its outlook 

Yesterday, the team at Morgans released an updated note on this ASX growth stock. 

It said Echo IQ has de-risked the commercial pathway since Morgan’s initiation via a $110m placement at $1.45 per share and a new distribution partnership with Pro Medicus.

HF FDA clearance remains the single biggest re-rating catalyst from here, and while timing has slipped slightly from our expected 4Q26 window, we remain confident on approval and expect feedback imminently. We lift our discounted target price to $1.85 (from $1.30), driven by a medium-term acceleration of revenues. Speculative Buy rating retained.

From yesterday’s closing price of $1.57, this indicates a further upside of nearly 18%. 

Elsewhere, Bell Potter recently tipped further upside for this ASX growth stock. 

It has a price target of $1.75 on Echo IQ shares. 

The broker said Echo IQ is making good progress by developing new products and securing long-term funding.

The broker warned, however, that the share price could experience volatility in coming months for several reasons:

• Revenue growth is expected to be modest over the next two years.
• The company will continue to spend significant cash.
• The share price will likely move based on announcements of new customer wins.

The post This ASX growth stock is up 500% this year and set to keep rising  appeared first on The Motley Fool Australia.

More reading

• What are experts saying about these red hot ASX shares?
• Up more than 550% in a year, why is this ASX biotech charging even higher?
• Up 230% in 5 years! Is this still a top Australian stock to buy?
• Is this exciting ASX tech stock a buy after its massive news?
• Pro Medicus just struck a revolutionary AI cardiology deal. Here’s why that matters

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.